Virtual Plenary 17 Participant Survey

1.Name
2.Organisation
3.Country
4.Occupation
5.How many plenaries have you attended so far?
6.Which sessions did you attend at RDA VP17?
7.How would you rate the content and format of the following program components?
Poor
Fair
Good
Very Good
Excellent
Did not attend
Day 1 - "Research Data in the Wider Data Ecosystem", Dr Jeni Tennison, the Open Data Institute
Day 1 - Joint IDCC/RDA Unconference 
Day 2 - Outputs and Adoption Session
Day 2 - Panel Session: Facilitating Greater Data Reuse: Lessons and Examples from Practice  
Day 3 - Plenary Session:"Building a Robust FAIR Biomedical Data Ecosystem". Dr Susan K. Gregurick, National Institutes of Health
Day 3 - "Open Science and Drug Discovery: Removing Barriers to Accelerate Research". Professor Richard Gold, McGill University, Centre for Intellectual Property
All days - Social Sessions ("Whit is Scots? An Introduction", Ceilidh Lessons, "RDA meets Edinburgh Fringe - Stuart Goldsmith"
All days - Networking sessions
Poster hall and sessions
8.How satisfied were you with the following communications used in the promotion of the event:
Poor
Fair
Good
Very Good
Excellent
Did not attend
Email campaigns from Organizing Committee
RDA website postings
Plenary Pathways 
Social media 
Webinars
Other
9.How would you rate the technology event platform (JunoLive) overall?
Poor
Fair
Good
Very Good
Excellent
10.How would you rate the following aspects of the plenary meeting technology platform?
Poor
Fair
Good
Very Good
Excellent
Did not attend
Usability of the overall site
Navigation 
Schedule layout
Support availability
Accessibility
Ability to see and interact with other attendees
Breakout meeting functionality
Poster area layout
11.Please provide any comments you have about the event platform used for VP17 (JunoLive)?
12.How would you rate the registration process?
Poor
Fair
Good
Very Good
Excellent
13.Please provide your feedback on the registration fee.
14.Please provide any other feedback, ideas or suggestions for future virtual, physical and hybrid RDA Plenary meetings.
15.What is the main benefit of attending the RDA plenaries for you?
16.Do you have any other comments about RDA VP17?
17.Are there any specific topics, areas or session formats you would like to see covered in future plenaries?